肺癌中MET外显子14改变：外显子跳跃延长半衰期
MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.
作者信息
Drilon Alexander
机构信息
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Weill Cornell Medical College, New York, New York.
出版信息
Clin Cancer Res. 2016 Jun 15;22(12):2832-4. doi: 10.1158/1078-0432.CCR-16-0229. Epub 2016 Mar 23.
Abstract
MET exon 14 alterations are a diverse group of mutations, many of which disrupt splice acceptor or donor sites leading to exon 14 skipping, impaired receptor degradation, and oncogenic transformation. These alterations are clinically targetable with MET-directed therapy. Clin Cancer Res; 22(12); 2832-4. ©2016 AACRSee related article by Tong et al., p. 3048.
摘要
MET外显子14改变是一组多样的突变，其中许多会破坏剪接受体或供体位点，导致外显子14跳跃、受体降解受损和致癌转化。这些改变在临床上可用MET靶向治疗。《临床癌症研究》；22(12)；2832 - 4。©2016美国癌症研究协会。见Tong等人的相关文章，第3048页。
相似文献
1
MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.
Clin Cancer Res. 2016 Jun 15;22(12):2832-4. doi: 10.1158/1078-0432.CCR-16-0229. Epub 2016 Mar 23.
2
[MET exon 14 splicing sites mutations: A new therapeutic opportunity in lung cancer].
Rev Mal Respir. 2018 Oct;35(8):796-812. doi: 10.1016/j.rmr.2018.01.011. Epub 2018 Aug 31.
3
Going After ex14 in NSCLC.
Cancer Discov. 2019 Aug;9(8):OF9. doi: 10.1158/2159-8290.CD-ND2019-006. Epub 2019 Jun 17.
4
The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
Lung Cancer. 2017 Jan;103:27-37. doi: 10.1016/j.lungcan.2016.11.011. Epub 2016 Nov 15.
5
[MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].
Zhongguo Fei Ai Za Zhi. 2018 Jul 20;21(7):553-559. doi: 10.3779/j.issn.1009-3419.2018.07.09.
6
MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer.
Oncotarget. 2016 Jul 5;7(27):41691-41702. doi: 10.18632/oncotarget.9541.
7
Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
J Thorac Oncol. 2016 Aug;11(8):1242-1245. doi: 10.1016/j.jtho.2016.06.013. Epub 2016 Jun 22.
8
MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.
Oncotarget. 2017 Jun 27;8(26):42428-42437. doi: 10.18632/oncotarget.16403.
9
Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study.
Cancer Genet. 2021 Aug;256-257:62-67. doi: 10.1016/j.cancergen.2021.04.005. Epub 2021 Apr 16.
10
Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
Curr Treat Options Oncol. 2020 Apr 18;21(4):33. doi: 10.1007/s11864-020-0723-5.
引用本文的文献
1
Targeting c-MET Alterations in Cancer: A Review of Genetic Drivers and Therapeutic Implications.
Cancers (Basel). 2025 Apr 29;17(9):1493. doi: 10.3390/cancers17091493.
2
MET Exon 14 Skipping and Novel Actionable Variants: Diagnostic and Therapeutic Implications in Latin American Non-Small-Cell Lung Cancer Patients.
Int J Mol Sci. 2024 Dec 22;25(24):13715. doi: 10.3390/ijms252413715.
3
Tepotinib for the Treatment of Lung Adenocarcinoma Harboring MET Y1003N Point Mutation: A Case Report.
Thorac Cancer. 2025 Jan;16(2):e15508. doi: 10.1111/1759-7714.15508. Epub 2024 Dec 15.
4
The Genetic Analysis and Clinical Therapy in Lung Cancer: Current Advances and Future Directions.
Cancers (Basel). 2024 Aug 19;16(16):2882. doi: 10.3390/cancers16162882.
5
RET splice site variants in medullary thyroid carcinoma.
Front Genet. 2024 Mar 19;15:1377158. doi: 10.3389/fgene.2024.1377158. eCollection 2024.
6
Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.
Clin Lung Cancer. 2023 Nov;24(7):641-650.e2. doi: 10.1016/j.cllc.2023.08.011. Epub 2023 Aug 13.
7
Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors.
Target Oncol. 2023 Jan;18(1):105-118. doi: 10.1007/s11523-022-00931-9. Epub 2022 Dec 2.
8
Integrative genomic analysis of drug resistance in exon 14 skipping lung cancer using patient-derived xenograft models.
Front Oncol. 2022 Oct 21;12:1024818. doi: 10.3389/fonc.2022.1024818. eCollection 2022.
9
Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients.
NPJ Precis Oncol. 2022 Nov 5;6(1):83. doi: 10.1038/s41698-022-00327-y.
10
Targeted Treatment of Non-Small Cell Lung Cancer: Focus on Capmatinib with Companion Diagnostics.
Onco Targets Ther. 2021 Nov 23;14:5321-5331. doi: 10.2147/OTT.S273357. eCollection 2021.
本文引用的文献
1
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis.
Clin Cancer Res. 2016 Jun 15;22(12):3048-56. doi: 10.1158/1078-0432.CCR-15-2061. Epub 2016 Feb 4.
2
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.
J Clin Oncol. 2016 Mar 1;34(7):721-30. doi: 10.1200/JCO.2015.63.4600. Epub 2016 Jan 4.
3
RNA mis-splicing in disease.
Nat Rev Genet. 2016 Jan;17(1):19-32. doi: 10.1038/nrg.2015.3. Epub 2015 Nov 23.
4
Gastrointestinal malignancies harbor actionable MET exon 14 deletions.
Oncotarget. 2015 Sep 29;6(29):28211-22. doi: 10.18632/oncotarget.4721.
5
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
J Clin Oncol. 2016 Mar 10;34(8):794-802. doi: 10.1200/JCO.2015.62.0674. Epub 2015 Jul 27.
6
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Cancer Discov. 2015 Aug;5(8):842-9. doi: 10.1158/2159-8290.CD-14-1467. Epub 2015 May 13.
7
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Cancer Discov. 2015 Aug;5(8):850-9. doi: 10.1158/2159-8290.CD-15-0285. Epub 2015 May 13.
8
The connection between splicing and cancer.
J Cell Sci. 2006 Jul 1;119(Pt 13):2635-41. doi: 10.1242/jcs.03053.
9
Somatic mutations lead to an oncogenic deletion of met in lung cancer.
Cancer Res. 2006 Jan 1;66(1):283-9. doi: 10.1158/0008-5472.CAN-05-2749.
10
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.
Cancer Res. 2005 Feb 15;65(4):1479-88. doi: 10.1158/0008-5472.CAN-04-2650.
Zotero 插件